

Performance (consolidated)

(¥ million)

	2017 (JGAAP)	2018 (JGAAP)	2019 (JGAAP)	2020 (IFRS)	2021 (IFRS)	2022 (IFRS)	2023 (IFRS) (estimated)
Revenue	101,448	114,716	116,637	121,859	137,484	144,175	147,000
Operating profit	17,079	20,644	21,668	27,202	32,948	30,049	33,500
Profit before tax	17,451	21,540	22,442	27,608	33,301	30,489	34,000
Profit attributable to owners of parent	12,953	16,302	16,866	19,540	24,986	22,812	26,000

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2021 (IFRS)	Sales 2022 (IFRS)	Sales 2023	
						Apr.-Sep.	Annual (estimated)
Viltepso	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	7,750	14,341	8,358	18,300
(Japan)				(4,059)	(4,139)	(2,188)	(4,800)
(U.S.)				(3,691)	(10,201)	(6,169)	(13,500)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	8,400	10,543	6,465	14,000
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	18,338	15,951	5,526	10,200
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	5,300	4,904	2,439	4,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	6,770	5,358	2,080	3,900
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,532	2,938	1,250	2,500
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	4,563	2,649	1,190	2,100
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	4,106	2,826	1,161	2,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,128	2,524	1,099	2,300
Erizas	dexamethasone cipeccilate	allergic rhinitis	Dec-2009	2,330	2,640	584	2,200
Profit in co-promotion				8,934	9,520	4,404	8,800
Revenues from the licensing of industrial property rights				33,207	30,714	18,580	38,000
Pharmaceuticals				120,650	121,988	60,988	125,000
Functional Food				16,834	22,187	12,325	22,000
Revenue				137,484	144,175	73,314	147,000